Prestige Consumer Healthcare Inc. (PBH)
NYSE NYSE Primary 
XFRA 
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.
PBH vs. NEOG: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?
PBH or NEOG: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?
Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
PBH vs. SYK: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts
Amylyx Pharmaceuticals, Inc. is upgraded to Strong Buy after positive phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia [PBH]. Avexitide met its primary endpoint, achieving a 55% reduction in severe hypoglycemic events, with strong statistical significance and a favorable safety profile. Key catalysts include an NDA submission for avexitide in PBH by end-2026 and medical data presentation in 2026; expansion into long-acting GLP-1 antagonist AMX0318 is underway.
PBH or SYK: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Prestige Consumer Healthcare Inc. (PBH) Q1 2027 Earnings Call Transcript
Prestige Consumer Healthcare Inc. (PBH) Q1 2027 Earnings Call Transcript
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape
Amylyx Pharmaceuticals NASDAQ: AMLX Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference.
Is the Options Market Predicting a Spike in Prestige Consumer Stock?
Investors need to pay close attention to PBH stock based on the movements in the options market lately.
Prestige Consumer Healthcare Inc. (PBH) Q4 2026 Earnings Call Transcript
Prestige Consumer Healthcare Inc. (PBH) Q4 2026 Earnings Call Transcript
Premium Brands: I Waited A Year For This Dip
Premium Brands has dropped into my $80–$90 buy range, presenting a compelling entry after a sharp pullback. PBH's M&A pipeline has slowed, but the Stampede acquisition adds significant U.S. capacity and growth potential, despite some near-term margin dilution. Management is shifting toward equity-funded acquisitions to protect leverage, likely resulting in higher share count but maintaining balance sheet flexibility.
